SGLT2 is "highly expressed in early lung adenocarcinoma and its precursor lesions, including atypical adenomatous hyperplasia ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of ...

How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Prescriptions for GLP-1 receptor agonists and SGLT2 ...

Sodium-glucose transporter 2 (SGLT2) inhibitors decrease the risk of acute kidney injury and severe hypoglycemia for those with diabetes, heart failure, and chronic kidney disease (CKD) but increase ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors used for the treatment of type 2 diabetes, and for heart failure, are associated with a nearly threefold increased risk for diabetic ketoacidosis (DKA ...

Statement of Need: Over the past 2 decades, increased clinical research has been focused on the sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the management of type 2 diabetes mellitus (T2DM ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...